Fortress Biotech, Inc. (FBIO): Lindsay A Md Rosenwald , CEO of Fortress Biotech, Inc. purchased 613 shares on Jun 1, 2016. The Insider buying transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.40 per share for a total value of $1,471.20 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 9, 2015, Lindsay A Md Rosenwald (CEO) purchased 586 shares at $2.41 per share price.
Fortress Biotech Inc: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Fortress Biotech Inc which led to swings in the share price. The shares opened for trading at $2.67 and hit $2.76 on the upside , eventually ending the session at $2.71, with a gain of 2.65% or 0.07 points. The heightened volatility saw the trading volume jump to 52,588 shares. The 52-week high of the share price is $4.66 and the company has a market cap of $131 M . The 52-week low of the share price is at $2.
Fortress Biotech Inc. formerly Coronado Biosciences Inc. is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer namely CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As of December 31 2014 TSO the microscopic eggs of the porcine whipworm was in Phase II study stage for the treatment of immune-mediated diseases such as Crohn’s disease (CD) ulcerative colitis (UC) or autism spectrum disorder (ASD). The Company’s CNDO-109 is a biologic that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells and as of December 31 2014 was in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML). The Company’s subsidiary Journey Medical Corporation (JMC) focuses on acquiring developing licensing and commercializing branded dermatology products.